364 related articles for article (PubMed ID: 18498916)
1. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.
Kuypers DR; de Jonge H; Naesens M; de Loor H; Halewijck E; Dekens M; Vanrenterghem Y
Clin Ther; 2008 Apr; 30(4):673-83. PubMed ID: 18498916
[TBL] [Abstract][Full Text] [Related]
2. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients.
Kuypers DR; Naesens M; Vermeire S; Vanrenterghem Y
Clin Pharmacol Ther; 2005 Oct; 78(4):351-61. PubMed ID: 16198654
[TBL] [Abstract][Full Text] [Related]
3. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
4. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.
van Schaik RH; van Agteren M; de Fijter JW; Hartmann A; Schmidt J; Budde K; Kuypers D; Le Meur Y; van der Werf M; Mamelok R; van Gelder T
Clin Pharmacol Ther; 2009 Sep; 86(3):319-27. PubMed ID: 19494809
[TBL] [Abstract][Full Text] [Related]
5. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.
Baldelli S; Merlini S; Perico N; Nicastri A; Cortinovis M; Gotti E; Remuzzi G; Cattaneo D
Pharmacogenomics; 2007 Sep; 8(9):1127-41. PubMed ID: 17924828
[TBL] [Abstract][Full Text] [Related]
6. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182
[TBL] [Abstract][Full Text] [Related]
7. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.
Naesens M; Kuypers DR; Streit F; Armstrong VW; Oellerich M; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2006 Nov; 80(5):509-21. PubMed ID: 17112807
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Vanrenterghem Y
Clin Pharmacol Ther; 2004 May; 75(5):434-47. PubMed ID: 15116056
[TBL] [Abstract][Full Text] [Related]
9. Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study.
Yin H; Qiu K; Hu XP; Li XB; Wang W; Liu LH; Zhang XD
Int J Clin Pract Suppl; 2014 Apr; (181):31-7. PubMed ID: 24673717
[TBL] [Abstract][Full Text] [Related]
10. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
[TBL] [Abstract][Full Text] [Related]
11. The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients.
Sánchez-Fructuoso AI; Maestro ML; Calvo N; Viudarreta M; Pérez-Flores I; Veganzone S; De la Orden V; Ortega D; Arroyo M; Barrientos A
Transplant Proc; 2009; 41(6):2313-6. PubMed ID: 19715905
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
[TBL] [Abstract][Full Text] [Related]
13. Comparison of pharmacokinetics of mycophenolic acid and its metabolites between living donor liver transplant recipients and deceased donor liver transplant recipients.
Shen B; Chen B; Zhang W; Mao H; Shen C; Deng X; Zhan X; Chen H
Liver Transpl; 2009 Nov; 15(11):1473-80. PubMed ID: 19877254
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses.
Kamar N; Marquet P; Gandia P; Muscari F; Lavayssière L; Esposito L; Guitard J; Canivet C; Peron JM; Alric L; Suc B; Saint-Marcoux F; Rostaing L
Ther Drug Monit; 2009 Aug; 31(4):451-6. PubMed ID: 19531983
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.
Oellerich M; Shipkova M; Schütz E; Wieland E; Weber L; Tönshoff B; Armstrong VW
Ther Drug Monit; 2000 Feb; 22(1):20-6. PubMed ID: 10688252
[TBL] [Abstract][Full Text] [Related]
16. Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia.
Hao C; Anwei M; Bing C; Baiyong S; Weixia Z; Chuan S; Erzhen C; Xiaxing D; Weihua Q; Weiping Y; Chenghong P; Hongwei L
Liver Transpl; 2008 Aug; 14(8):1165-73. PubMed ID: 18668650
[TBL] [Abstract][Full Text] [Related]
17. Limits to intensified mycophenolate mofetil dosing in kidney transplantation.
Kiberd BA; Lawen J; Daley C
Ther Drug Monit; 2012 Dec; 34(6):736-8. PubMed ID: 23007746
[TBL] [Abstract][Full Text] [Related]
18. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
van Gelder T; Hilbrands LB; Vanrenterghem Y; Weimar W; de Fijter JW; Squifflet JP; Hené RJ; Verpooten GA; Navarro MT; Hale MD; Nicholls AJ
Transplantation; 1999 Jul; 68(2):261-6. PubMed ID: 10440399
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
Staatz CE; Tett SE
Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
[TBL] [Abstract][Full Text] [Related]
20. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation.
Gourishankar S; Houde I; Keown PA; Landsberg D; Cardella CJ; Barama AA; Dandavino R; Shoker A; Pirc L; Wrobel MM; Kiberd BA
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1282-9. PubMed ID: 20498245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
